Sam Brusco, Associate Editor10.03.23
SurGenTec has received clearance from the U.S. Food and Drug Administration (FDA) for its TiLink-P minimally invasive compression implant for chronic sacroiliac (SI) joint pain.
TiLink-P combines compression across the SI joint with a posterior implantation approach to stabilize the painful region and stimulate healing. Implantation needs only one small incision and one integrated implant, according to the company. TiLink-P’s form factor allows dispensing copious amounts of bone graft in and around the implant, as well.
Using the standalone implant, surgeons can transfix the SI joint by spanning the ilium and sacrum via the muscle-sparing, posterior approach. SurGenTech said rigorous biomechanical and cadaveric studies have validated the device, and no additional hardware is needed to support the procedure.
The 3D-printed titanium implant features Nanotex surface technology and a trellis system designed to help promote osteointegration. SurGenTec said it’s currently collaborating with navigation companies to use platforms that work together with TiLink.
"We are thrilled to introduce TiLink Posterior Sacroiliac Joint Fusion System," SurGenTec’s CEO Travis Greenhalgh told the press. "By combining the power of compression across the SI joint with the muscle-sparing posterior approach and the ability to reinforce with bone graft, TiLink offers surgeons a new and efficient way to enhance healing in patients. We anticipate that this groundbreaking technology will have a profound impact on patient outcomes and improve the overall quality of care."
In June, the company’s TiLink lateral sacroiliac fusion system received FDA clearance as well.
TiLink-P combines compression across the SI joint with a posterior implantation approach to stabilize the painful region and stimulate healing. Implantation needs only one small incision and one integrated implant, according to the company. TiLink-P’s form factor allows dispensing copious amounts of bone graft in and around the implant, as well.
Using the standalone implant, surgeons can transfix the SI joint by spanning the ilium and sacrum via the muscle-sparing, posterior approach. SurGenTech said rigorous biomechanical and cadaveric studies have validated the device, and no additional hardware is needed to support the procedure.
The 3D-printed titanium implant features Nanotex surface technology and a trellis system designed to help promote osteointegration. SurGenTec said it’s currently collaborating with navigation companies to use platforms that work together with TiLink.
"We are thrilled to introduce TiLink Posterior Sacroiliac Joint Fusion System," SurGenTec’s CEO Travis Greenhalgh told the press. "By combining the power of compression across the SI joint with the muscle-sparing posterior approach and the ability to reinforce with bone graft, TiLink offers surgeons a new and efficient way to enhance healing in patients. We anticipate that this groundbreaking technology will have a profound impact on patient outcomes and improve the overall quality of care."
In June, the company’s TiLink lateral sacroiliac fusion system received FDA clearance as well.